Antibacterial efficacy of inhaled squalamine in a rat model of chronic Pseudomonas aeruginosa pneumonia

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 10, 2012, Pages 2452-2458

  Hraiech, Sami ^a,b   Brégeon, Fabienne ^a,b   Brunel, Jean Michel ^a   Rolain, Jean Marc ^a   Lepidi, Hubert ^a,c   Andrieu, Véronique ^a   Raoult, Didier ^a   Papazian, Laurent ^a,b   Roch, Antoine ^a,b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL NORD   (France)

^c TIMONE HOSPITAL   (France)

Author keywords

Aerosols; Animal models; Anti infectious drugs; Colonization

Indexed keywords

COLISTIN; SODIUM CHLORIDE; SQUALAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; BACTERIAL STRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; LUNG; LUNG WEIGHT; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; RAT; SCORING SYSTEM;

ADMINISTRATION, INHALATION; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; CHOLESTANOLS; CHRONIC DISEASE; COLISTIN; DISEASE MODELS, ANIMAL; LUNG; MALE; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME;

EID: 84866602844     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks230     Document Type: Article

References (31)

1. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J Infect Dis 2008; 197: 1079-81.
2. Bassetti M, Ginocchio F, Mikulska M. New treatment options against gram-negative organisms. Crit Care 2011; 15: R21.
3. Maviglia R, Nestorini R, Pennisi M. Role of old antibiotics in multidrug resistant bacterial infections. Curr Drug Targets 2009; 10: 895-905.
4. Falagas ME, Kasiakou SK. Toxicity of polymyxins: a systematic review of the evidence from old and recent studies. Crit Care 2006; 10: R27.
5. Livermore DM, on behalf of the British Society for Antimicrobial Chemotherapy Working Party on the Urgent Need: Regenerating Antibacterial Drug Discovery and Development. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011; 66: 1941-4.
6. Alhanout K, Rolain JM, Brunel JM. Squalamine as an example of a new potent antimicrobial agents class: a critical review. Curr Med Chem 2010; 17: 3909-17.
7. Brunel JM, Salmi C, Loncle C et al. Squalamine: a polyvalent drug of the future? Curr Cancer Drug Targets 2005; 5: 267-72.
8. Salmi C, Loncle C, Vidal N et al. Squalamine: an appropriate strategy against the emergence of multidrug resistant gram-negative bacteria? PLoS One 2008; 3: e2765.
9. Djouhri-Bouktab L, Alhanout K, Andrieu V et al. Squalamine ointment for Staphylococcus aureus skin decolonization in a mouse model. J Antimicrob Chemother 2011; 66: 1306-10.
10. Zasloff M, Adams AP, Beckerman B et al. Squalamine as a broad-spectrum systemic antiviral agent with therapeutic potential. Proc Natl Acad Sci USA 2011; 108: 15978-83.
11. Alhanout K, Brunel JM, Raoult D et al. In vitro antibacterial activity of aminosterols against multidrug-resistant bacteria from patients with cystic fibrosis. J Antimicrob Chemother 2009; 64: 810-4.
12. Alhanout K, Malesinki S, Vidal N et al. New insights into the antibacterial mechanism of action of squalamine. J Antimicrob Chemother 2010; 65: 1688-93.
13. Alhanout K, Brunel JM, Ranque S et al. In vitro antifungal activity of aminosterols against moulds isolated from cystic fibrosis patients. J Antimicrob Chemother 2010; 65: 1307-9.
14. Sermet-Gaudelus I, Le Cocquic Y, Ferroni A et al. Nebulized antibiotics in cystic fibrosis. Paediatr Drugs 2002; 4: 455-67.
15. Palmer LB, Smaldone GC, Chen JJ et al. Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit. Crit Care Med 2008; 36: 2008-13.
16. Abu-Salah T, Dhand R. Inhaled antibiotic therapy for ventilatorassociated tracheobronchitis and ventilator-associated pneumonia: an update. Adv Ther 2011; 28: 728-47.
17. Lu Q, Yang J, Liu Z et al. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med 2011; 184: 106-15.
18. Alhanout K, Brunel JM, Dubus JC et al. Suitability of a new antimicrobial aminosterol formulation for aerosol delivery in cystic fibrosis. J Antimicrob Chemother 2011; 66: 2797-800.
19. Kukavica-Ibrulj I, Bragonzi A, Paroni M et al. In vivo growth of Pseudomonas aeruginosa strains PAO1 and PA14 and the hypervirulent strain LESB58 in a rat model of chronic lung infection. J Bacteriol 2008; 190: 2804-13.
20. Chiang SR, Chuang YC, Tang HJ et al. Intratracheal colistin sulfate for BALB/c mice with early pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Crit Care Med 2009; 37: 2590-5.
21. Lu Q, Girardi C, Zhang M et al. Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa. Intensive Care Med 2010; 36: 1147-55.
22. Sakagami M. In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. Adv Drug Deliv Rev 2006; 58: 1030-60.
23. Schmitt HJ, Bernard EM, Häuser M et al. Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1988; 32: 1676-9.
24. Cicogna CE, White MH, Bernard EM et al. Efficacy of prophylactic aerosol amphotericin B lipid complex in a rat model of pulmonary aspergillosis. Antimicrob Agents Chemother 1997; 41: 259-61.
25. Marquette CH, Wermert D, Wallet F et al. Characterization of an animal model of ventilator-acquired pneumonia. Chest 1999; 115: 200-9.
26. Cash HA, Woods DE, McCullough B et al. A rat model of chronic respiratory infection with Pseudomonas aeruginosa. Am Rev Respir Dis 1979; 119: 453-9.
27. Bregeon F, Papazian L, Visconti A et al. Relationship of microbiologic diagnostic criteria to morbidity and mortality in patients with ventilatorassociated pneumonia. JAMA 1997; 277: 655-62.
28. Meers P, Neville M, Malinin V et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008; 61: 859-68.
29. Badia JR, Soy D, Adrover M et al. Disposition of instilled versus nebulized tobramycin and imipenem in ventilated intensive care unit (ICU) patients. J Antimicrob Chemother 2004; 54: 508-14.
30. Goldstein I, Wallet F, Nicolas-Robin A et al. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am J Respir Crit Care Med 2002; 166: 1375-81.
31. Herbst RS, Hammond LA, Carbone DP et al. A phase I/IIA trial of continuous five-day infusion of squalamine lactate (MSI-1256F) plus carboplatin and paclitaxel in patients with advanced non-small cell lung cancer. Clin Cancer Res 2003; 9: 4108-15.